Clinical Trial Update: Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating alpelisib, fulvestrant, and dapagliflozin for HR+, HER2-, PIK3CA-mutant metastatic breast cancer. Status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Dapagliflozin (dapagliflozin)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Saint Luke's Health System | Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: UNKNOWN